Upper Extremity Tremor Clinical Trial
Official title:
123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor (AIM)
This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.
This is a prospective, multi-center, non-randomized, open-label, out patient clinical trial
which will include up to 90 subjects, male or female, 40 years of age or older.
This study is designed to obtain an imaging training set that will be used to evaluate
images in future trials. Up to ninety subjects with upper extremity tremor for less than 2
years duration will be enrolled. Of these, at least thirty Parkinsonian syndromes subjects
and at least thirty non-Parkinsonian syndromes subjects as diagnosed by a MDS will be
enrolled.
Subjects will participate in three study visits over the course of the study period. The
screening visit will include an assessment of eligibility as well as the collection of the
MDS diagnosis. The second visit, during which all subjects receive a single intravenous
injection of 123I-ALTROPANE® followed by SPECT imaging, will include appropriate safety
assessments before and after dosing. The third visit will include follow-up safety. The
subjects' participation in the study will range between 30 and 40 days.
;
Observational Model: Cohort, Time Perspective: Prospective